Xinteza API Ltd.a biosynthetic technology company, revealed the Discovery of a new catalytic enzymeable to solve one of the biggest bottlenecks that has so far made design more sustainable and cost-effective cannabinoid biosynthesis Production Systems, in research led by Professor Asaf Aharoni In the Weizmann Institute of Science.
Xinteza has recently unveiled Discoveries for a patent-pending entirely new non-cannabis source of cannabinoid biosynthesis-related genes and enzymes. This newly discovered gene pool contains a novel prenyl transferase enzyme.
The prenylation stage in cannabinoid biosynthesis is the final and most important step in the formation of CBGA, the “mother” molecule of most other known cannabinoids such as THCA, CBDA and CBCA, however, the original enzyme used by the cannabis sativa plant loses a significant portion of its activity when introduced into yeast and bacterial expression systems. Several alternative genes have been proposed by different research groups over the years to circumvent this prenylation blockade, but most suffered from serious shortcomings in utility, such as: B. compromised chemical kinetics or operational freedom issues.
According to the company, the new prenyl transferase enzyme PT-X solves this bottleneck by offering improved catalytic activity in the range of 5 times better than the original cannabis sativa enzyme, as well as high compatibility for introduction into microorganisms. industrial production systems based on cannabinoid biosynthesis.
“As we expand the commercialization and collaboration activities of our IP, we are highly motivated by this pivotal discovery of such an important novel enzyme. The flexibility and efficiency of PT-X has the potential to dramatically improve the cost-effectiveness of current cannabinoid biosynthetic production due to its significant advantages over existing prenyl transferase solutions,” explained Alon Gal, CEO of Xinteza. “We continue to optimize processes of cannabinoid biosynthesis on a commercial scale with…
